Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

After Theranos

The implosion of blood diagnostics developer Theranos has raised the question: What is feasibly detectible in a drop of blood? Emily Waltz reports.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Washburn, A.L. et al. Procedia Eng. 25, 63–66 (2011).

    Article  CAS  Google Scholar 

  2. Dittmer, W.U. et al. Clin. Chim. Acta 411, 868–873 (2010).

    Article  CAS  Google Scholar 

  3. Choi, J. et al. Biosens. Bioelectron. 85, 1–7 (2016).

    Article  CAS  Google Scholar 

  4. Wang, Y. et al. Biosens. Bioelectron. 70, 61–68 (2015).

    Article  Google Scholar 

  5. Phipps, W.S. et al. J. Vis. Exp. 93, e51743 (2014).

    Google Scholar 

  6. Mor, O. et al. J. Clin. Microbiol. 53, 3458–3465 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Waltz, E. After Theranos. Nat Biotechnol 35, 11–15 (2017). https://doi.org/10.1038/nbt.3761

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3761

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing